From Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK:

0220-NURTEC-D20028-RT-V1

0220-NURTEC-D20028-RT-V1—

Photo by Biohaven Pharmaceutical

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Special Report
As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future
Hyperinflation in rents is over
Hughes Marino

Xconomy Insight · Special Report
Biotech Startups: How to Succeed in a COVID-19 World
Industry experts explain what it takes to launch a new biotech company

Xconomy on Demand

We offer a number of ways to subscribe for free!